Global Allergic Asthma Therapeutics Market Size By Type (ASM-8, AXP-1275), By Application (Clinic, Research Center), By Region, And Segment Forecasts, 2023 to 2032

The Global Allergic Asthma Therapeutics Market was valued at USD 21.4 billion in 2023 and is projected to reach USD 38.1 billion by 2031, expanding at a CAGR of 7.3% during the forecast period from 2023 to 2031. The market growth is fueled by the increasing global prevalence of allergic asthma, advancements in biologic therapies, and rising healthcare spending. Biologic drugs that target immunoglobulin E (IgE) and interleukins are revolutionizing asthma treatment, significantly improving outcomes for patients with moderate-to-severe allergic asthma.

Drivers:

1. Rising Prevalence of Allergic Asthma:

Global allergic asthma cases are on the rise, driven by increasing urbanization, air pollution, and changing lifestyles. According to the WHO, over 260 million people were affected by asthma in 2022, with allergic asthma being the most common subtype.

2. Growth in Biologics and Targeted Therapy:

Biologic therapies like omalizumab, mepolizumab, and dupilumab are offering personalized treatment options. These monoclonal antibodies target specific inflammatory pathways, providing relief for patients who don’t respond well to traditional corticosteroids.

3. Increased R&D and Clinical Approvals:

Pharmaceutical firms are investing heavily in the development of novel drugs for allergic asthma. Multiple pipeline drugs are progressing through clinical trials, aimed at better safety profiles and long-term management.

Restraints:

1. High Cost of Biologic Therapies:

Advanced biologics, while effective, come at a high price point, limiting access for patients in low- and middle-income countries.

2. Limited Diagnosis and Awareness:

Despite its growing prevalence, allergic asthma remains underdiagnosed in many regions, particularly in rural areas. This results in delayed or inappropriate treatment.

Opportunity:

1. Expansion in Emerging Markets:

Rapid improvements in healthcare infrastructure across Asia-Pacific and Latin America are enabling greater diagnosis and treatment access, creating new growth avenues.

2. Integration of Digital Health Solutions:

Digital platforms for asthma monitoring, medication reminders, and teleconsultations are enhancing treatment adherence and outcomes. This trend is opening new opportunities for companies integrating digital tools with therapeutics.

Market by System Type Insights:

Based on therapy type, Biologic Drugs accounted for the largest share in 2023 due to their proven efficacy in managing moderate-to-severe allergic asthma. This segment is expected to continue dominating the market, supported by increasing approvals and broader insurance coverage. However, the Inhaled Corticosteroids and Combination Therapies segment remains essential for first-line management of mild-to-moderate cases and is expected to grow steadily.

Market by End-use Insights:

By end-use, Hospitals and Specialty Clinics emerged as the leading segment in 2023, contributing over 60% of total market revenue. The availability of specialist care, advanced diagnostics, and biologic administration services support this dominance. Meanwhile, Homecare Settings are expected to gain momentum due to the increasing use of portable inhalers and self-administered injectables.

Market by Regional Insights:

North America led the market in 2023, owing to its high disease awareness, advanced healthcare infrastructure, and early adoption of biologics. Europe followed closely, driven by supportive reimbursement policies and robust clinical research. Asia-Pacific is projected to witness the highest growth through 2031, fueled by rising pollution levels, urbanization, and expanding access to biologic therapies in countries like China and India.

Competitive Scenario:

Key players in the market include AstraZeneca plc, GlaxoSmithKline plc, Sanofi S.A., Novartis AG, Teva Pharmaceuticals, Regeneron Pharmaceuticals, and Boehringer Ingelheim. These companies are actively engaged in expanding their allergic asthma portfolios through clinical trials, regulatory approvals, and strategic partnerships.

Key Developments:

2024: Sanofi and Regeneron received expanded FDA approval for dupilumab in adolescents with allergic asthma.

2023: AstraZeneca launched a Phase III trial for tezepelumab in pediatric allergic asthma.

2023: GSK introduced a digital asthma management platform integrating AI-based patient monitoring with its therapeutic offerings.

Scope of Work – Global Allergic Asthma Therapeutics Market

FAQs:

1) What is the current market size of the Global Allergic Asthma Therapeutics Market?

The market was valued at USD 21.4 billion in 2023.

2) What is the major growth driver of the Global Allergic Asthma Therapeutics Market?

The major growth driver is the rising adoption of biologic therapies and increasing asthma prevalence worldwide.

3) Which is the largest region during the forecast period in the Global Allergic Asthma Therapeutics Market?

North America accounted for the largest share in 2023 and is expected to maintain its lead through 2031.

4) Which segment accounted for the largest market share in the Global Allergic Asthma Therapeutics Market?

The Biologic Drugs segment held the largest share by therapy type in 2023.

5) Who are the key market players in the Global Allergic Asthma Therapeutics Market?

Key players include AstraZeneca, GSK, Sanofi, Novartis, Teva Pharmaceuticals, Regeneron, and Boehringer Ingelheim.